Harmony Biosciences Holdings, Inc. (HRMY) Form 8-K — Oct 13, 2026
$HRMYForm 8-KItems 5.02, 7.01, 9.01Filed Oct 13, 2026, 8:00 AM ET0001104659-26-115282Original filing
Harmony Biosciences announced a planned CEO succession: Jeffrey M. Dayno, M.D. will retire as President, CEO and director effective December 31, 2026, then serve as a non-executive advisor through 2027. Peter Anastasiou, current Sr.
Key figures
- Guidance
- Full-year 2026 WAKIX net revenue guidance of $1.0 billion to $1.04 billion (reiterated)
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.